相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。From identification of the BTK kinase to effective management of leukemia
C. I. E. Smith
ONCOGENE (2017)
Optimal management of ALK-positive NSCLC progressing on crizotinib
Giulio Metro et al.
LUNG CANCER (2017)
ALK: a tyrosine kinase target for cancer therapy
Vijaykumar R. Holla et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases
Hideko Isozaki et al.
CANCER RESEARCH (2016)
Ibrutinib for treatment of chronic lymphocytic leukemia
Cory M. Vela et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
Erin Larkins et al.
CLINICAL CANCER RESEARCH (2016)
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
Vivek Asati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib
Sandeep Kodityal et al.
LUNG CANCER (2016)
A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation
E. Grassilli et al.
ONCOGENE (2016)
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
Y. Li et al.
ONCOGENE (2016)
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Neuroblastoma: Molecular Pathogenesis and Therapy
Chrystal U. Louis et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Sean Khozin et al.
CLINICAL CANCER RESEARCH (2015)
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2015)
A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy
Nick Ming Yau et al.
CURRENT CANCER DRUG TARGETS (2015)
The Proto-oncogene Transcription Factor Ets1 Regulates Neural Crest Development through Histone Deacetylase 1 to Mediate Output of Bone Morphogenetic Protein Signaling
Chengdong Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Ibrutinib for the treatment of Waldenstrom macroglobulinemia
Rajshekhar Chakraborty et al.
EXPERT REVIEW OF HEMATOLOGY (2015)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner
J. Sun et al.
ONCOGENE (2014)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders Recent progress and therapeutic perspectives
Seng-Lai Tan et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Nai-Kong V. Cheung et al.
NATURE REVIEWS CANCER (2013)
Ubiquitin and Membrane Protein Turnover: From Cradle to Grave
Jason A. MacGurn et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 81 (2012)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
ALK signaling and target therapy in anaplastic large cell lymphoma
Fabrizio Tabbo et al.
FRONTIERS IN ONCOLOGY (2012)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
Takaaki Sasaki et al.
CANCER RESEARCH (2010)
Neuroblastoma: Biology, Prognosis, and Treatment
Julie R. Park et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Medical Progress: Recent Advances in Neuroblastoma.
John M. Maris
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Identification of ALK as a major familial neuroblastoma predisposition gene
Yael P. Mosse et al.
NATURE (2008)
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George et al.
NATURE (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization
J Jin et al.
CURRENT BIOLOGY (2004)
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
A Motegi et al.
JOURNAL OF CELL SCIENCE (2004)
Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway
B Souttou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
